1. Home
  2. CARM vs COHN Comparison

CARM vs COHN Comparison

Compare CARM & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CARM
  • COHN
  • Stock Information
  • Founded
  • CARM 2016
  • COHN 1999
  • Country
  • CARM United States
  • COHN United States
  • Employees
  • CARM N/A
  • COHN N/A
  • Industry
  • CARM Biotechnology: Pharmaceutical Preparations
  • COHN Investment Bankers/Brokers/Service
  • Sector
  • CARM Health Care
  • COHN Finance
  • Exchange
  • CARM Nasdaq
  • COHN Nasdaq
  • Market Cap
  • CARM 19.7M
  • COHN 18.5M
  • IPO Year
  • CARM N/A
  • COHN N/A
  • Fundamental
  • Price
  • CARM $0.45
  • COHN $9.50
  • Analyst Decision
  • CARM Hold
  • COHN
  • Analyst Count
  • CARM 5
  • COHN 0
  • Target Price
  • CARM $4.57
  • COHN N/A
  • AVG Volume (30 Days)
  • CARM 512.7K
  • COHN 4.3K
  • Earning Date
  • CARM 03-31-2025
  • COHN 03-05-2025
  • Dividend Yield
  • CARM N/A
  • COHN 10.42%
  • EPS Growth
  • CARM N/A
  • COHN N/A
  • EPS
  • CARM N/A
  • COHN 2.35
  • Revenue
  • CARM $20,268,000.00
  • COHN $89,555,000.00
  • Revenue This Year
  • CARM $46.34
  • COHN N/A
  • Revenue Next Year
  • CARM N/A
  • COHN N/A
  • P/E Ratio
  • CARM N/A
  • COHN $4.09
  • Revenue Growth
  • CARM 41.13
  • COHN 63.18
  • 52 Week Low
  • CARM $0.38
  • COHN $6.10
  • 52 Week High
  • CARM $2.77
  • COHN $12.82
  • Technical
  • Relative Strength Index (RSI)
  • CARM 44.17
  • COHN 43.32
  • Support Level
  • CARM $0.43
  • COHN $9.43
  • Resistance Level
  • CARM $0.50
  • COHN $9.79
  • Average True Range (ATR)
  • CARM 0.05
  • COHN 0.30
  • MACD
  • CARM 0.00
  • COHN 0.02
  • Stochastic Oscillator
  • CARM 28.16
  • COHN 37.50

About CARM Carisma Therapeutics Inc.

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

Share on Social Networks: